Brief: Stayble Therapeutics Q4 EBIT Loss SEK 3.2 Mln
25/02/2025 07:41
Feb 25 (Reuters) - Stayble Therapeutics AB STABL.ST :
* Q4 EBIT LOSS SEK 3.2 MILLION
* BOARD DOES NOT INTEND TO PROPOSE ANY DIVIDEND AT 2025 AGM
Source text: ID:nWkr4LJ0jp
Further company coverage: STABL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Stayble Therapeutics AB
See all newsBrief: Stayble Therapeutics Delisted From Nasdaq First North Growth Market
Brief: Stayble Therapeutics To Apply For Bankruptcy
Brief: Stayble Therapeutics Q1 EBIT Loss Narrows To SEK 6.9 Mln
Brief: Stayble Therapeutics Enters Into LoI On Potential Strategic Collaboration, Financing
Brief: Stayble Therapeutics Q4 Oper Loss To SEK 1.5 Mln